# A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma

> **NCT00476554** · PHASE2 · TERMINATED · sponsor: **Cyclacel Pharmaceuticals, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Cutaneous T-cell Lymphoma (CTCL)

## Interventions

- **DRUG:** Sapacitabine

## Key facts

- **NCT ID:** NCT00476554
- **Lead sponsor:** Cyclacel Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04
- **Primary completion:** 2012-03-01
- **Final completion:** 2012-03-01
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** slow accrual and financial resource limitation
- **Last updated:** 2021-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00476554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00476554, "A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00476554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*